[{"NetIncomeLossConverted_1_Q3_USD":842100000.0,"NetIncomeLossConverted_3_Q3_USD":2364000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":105500000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":108300000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":1387100000.0,"EarningsPerShareDiluted_1_Q3_USD":7.39,"EarningsPerShareDiluted_3_Q3_USD":20.36,"StockholdersEquity_0_Q3_USD":10125500000.0,"RevenuesConverted_1_Q3_USD":2294000000.0,"RevenuesConverted_3_Q3_USD":6074200000.0,"Assets_0_Q3_USD":16084000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":113900000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":116100000.0,"EarningsPerShareBasic_3_Q3_USD":21.83,"EarningsPerShareBasic_1_Q3_USD":7.98,"Ticker":"REGN","CIK":"872589","name":"REGENERON PHARMACEUTICALS, INC.","OfficialName":"Regeneron Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"77738004554.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"SP500","filed":"20201105"}]